|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>RESULTS:</b><i>CYP1B1</i> rs1056836 variant was associated with decreased risk of PCa [odds ratio (OR): 0.80; 95% confidence interval (CI): 0.68-0.99, <i>P</i> = 0.041].
|
29344273 |
2018 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, this meta-analysis suggests that Leu432Val polymorphism is associated with ovarian cancer, lung cancer, and endometrial cancer risk; Asn453Ser and Arg48Gly polymorphisms are associated with endometrial cancer risk among Caucasians, Ala119Ser polymorphism is associated with prostate cancer risk, and Ala119Ser polymorphism is associated with breast cancer risk in Caucasians.
|
25475389 |
2015 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, based on 17 eligible studies, we found that the CYP1B1 Leu432Val polymorphism was associated with an increased risk of prostate cancer, while no association of bladder cancer was observed.
|
24453031 |
2014 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results suggest that L432V, N453S, and A119S polymorphisms of CYP1B1 might be associated with the susceptibility of PCa.
|
23861929 |
2013 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was evidence of altered risk of developing PCa for variants in ESR1, CYP1A1, and CYP1B1, however, only CYP1B1 rs1056836 retained significance after adjustment for multiple comparisons.
|
22549291 |
2013 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prostate cancer risk and aggressiveness associated with the CYP1B1 4326C/G (Leu432Val) polymorphism: a meta-analysis of 2788 cases and 2968 controls.
|
22504876 |
2012 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis provides evidence that CYP1B1 Leu432Val polymorphism is not associated with prostate cancer risk overall with the exception in Asians.
|
22327650 |
2012 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
A common C-G-C-C-G-A haplotype for rs2567206-rs2551188-rs2617266-rs10012-rs1056836-rs1800440 showed an inverse association with PCa risk in Hispanic Caucasians (OR = 0.19, P = 0.04, 95% CI = 0.04-0.95) and with aggressive disease status (i.e.
|
18544568 |
2008 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The VV (high activity) genotype of the V432L polymorphism from CYP1B1 (odds ratio [OR] = 1.36; 95% CI, 1.03 to 1.79; P = .031), and the long allele (> 175 bp) of the TTTA repeat from CYP19 (OR, 1.26; 95% CI, 1.08 to 1.47; P = .003) were significantly associated with the risk of prostate cancer.
|
17704407 |
2007 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Because CYP1B1 is involved in hormone and carcinogen metabolism, and given the disparate rates of prostate cancer among ethnic groups, we also evaluated the association of the CYP1B1 Leu432Val polymorphism with prostate cancer risk in a pilot case-control study.
|
11221602 |
2000 |